Navigation Links
New Study Shows Promise For Women Needing Mesh-Augmented Pelvic Organ Prolapse (POP) Repair

CLEVELAND, Dec. 11, 2012 /PRNewswire-USNewswire/ -- Imalux® Corporation, manufacturer of the Niris® Imaging System announces that the Niris 1300e has been successfully used to help physicians evaluate women for their suitability and response to mesh-augmented pelvic organ prolapse (POP) repair.  The Imalux Niris 1300e Imaging System was used by researchers at North Shore Long Island Jewish Health System.  They were able to image previously placed mesh located in the vaginal epithelium, and were able to measure the thickness of the epithelial tissue. These studies have generated valuable information relative to the success of the vaginal mesh placement procedures.  Both studies were presented at the recent American Urogynecologic Society Annual Meeting.  


Earlier this year, the FDA issued a series of safety communications and requirements to manufacturers of vaginal mesh to do 3-year follow-up studies on patients with vaginal mesh implants.  Imalux believes that physicians using the Niris 1300e to image implanted mesh is a valuable tool to assist those mesh manufacturers during their post-market studies.  Other imaging technologies, such as X-rays, CT scans, MRI's, and Ultrasound are not able to reach the resolution necessary to monitor the vaginal epithelium. Niris is FDA cleared, carries the CE Mark and is being used by leading hospitals and physicians in the USA and Europe.

In addition, Imalux believes the Niris 1300e is not only a valuable preoperative and postoperative screening tool for mesh-augmented repair candidates and recipients, but also for the entire market of postmenopausal women interested in the monitoring of hormonal treatment.  The combination of noninvasiveness, ease of use, and the measurement tools of the Niris 1300e, are expected to make Niris 1300e the new imaging standard for mesh related documentation and epithelial diseases.

About Imalux® and the Niris® Imaging System

Imalux Corporation, based in Cleveland, Ohio, is a leader in the development and commercialization of site of care imaging systems utilizing harmless, near-infrared light.  The Imalux technology platform, sold under the Niris® registered trademark, is based on our proprietary and patented application of Optical Coherence Tomography (OCT) to provide real-time, high resolution, cross sectional imaging of tissue microstructures.  Niris is a tool to aid in the diagnosis of a variety of diseases, early detection of abnormalities, guidance of biopsy and surgery, and post-treatment surveillance in a multitude of clinical applications.


SOURCE Imalux Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Finds Utilizing Integrated Medical and Pharmacy Data Improves Ability to Forecast Use of High-cost Specialty Treatments
2. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
3. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
4. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
5. Shingles Vaccine is Safe, According to New Study
6. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
7. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
8. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
9. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
10. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
11. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... --> adds "Global ... and "Investigation Report on China Repaglinide ... 2021 forecasts data and information to ... . --> ...
(Date:11/26/2015)... 26, 2015 ... "Radioimmunoassay Market by Type (Reagents & ... Academics, Clinical Diagnostic Labs), Application (Research, Clinical ... 2020" report to their offering. ... addition of the "Radioimmunoassay Market by ...
(Date:11/25/2015)...  The total global healthcare industry is expected to grow ... Latin America has the highest projected growth at ... Japan ), is second with growth projected at 11.5%. ... healthcare expenditure. In 2013-2014, total government funded healthcare was nearly ... to 41.2% in 2013-2014. In real terms, out of pocket ...
Breaking Medicine Technology:
(Date:11/27/2015)... CO (PRWEB) , ... November 27, 2015 , ... According ... cities are not changing the way that they are handling security in light of ... police and security presence in an attempt to stop an attack from reaching U.S. ...
(Date:11/27/2015)... County, CA (PRWEB) , ... November 27, 2015 , ... ... season , The company is offering customers 10% off of their purchase of lice ... any treatment at full price. According to a company spokesperson. “Finding lice is a ...
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec ... Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end users ... Dynamics SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership status ...
(Date:11/27/2015)... IL (PRWEB) , ... November 27, 2015 , ... ... of the largest, most successful and prominent nonprofit healthcare organizations in the country. ... governance involvement with various organizations, and helped advance the healthcare industry as a ...
(Date:11/26/2015)... ... ... Inevitably when people think Thanksgiving, they also think Holiday sales and start ... and Cyber Monday massage chair sales to receive the best pricing on ... find the best massage chair deals, they can see all of the coupons in ...
Breaking Medicine News(10 mins):